US2019046522A1PendingUtilityA1

Pharmaceutical formulation containing irritant

Assignee: PURDUE PHARMA LPPriority: Aug 6, 2001Filed: Oct 12, 2018Published: Feb 14, 2019
Est. expiryAug 6, 2021(expired)· nominal 20-yr term from priority
Inventors:Richard Sackler
A61K 9/1694A61K 31/485A61K 9/205A61K 9/5026A61K 9/1617A61K 9/5089A61K 9/4866A61K 9/4808A61K 9/1272A61K 9/2013A61K 9/2081A61K 9/1611A61K 9/1652A61K 9/5078A61K 9/1647A61K 9/1635A61K 9/0053A61K 47/18A61K 31/135A61K 31/165A61K 9/2054A61K 9/2027
75
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.

Claims

exact text as granted — not AI-modified
1 - 28 . (canceled) 
     
     
         29 . An abuse-deterrent oral controlled release dosage form comprising particles comprising a homogeneous mixture comprising:
 a therapeutically effective amount of a CNS stimulant,   an aversive agent, and   a material selected from the group consisting of gums, cellulose ethers, acrylic resins, waxes, shellac, oils and mixtures of any of the foregoing,   the aversive agent and the material are in the amounts that spoil or hinder the pleasure of obtaining a high from the CNS stimulant when the dosage form is tampered with by crushing, shearing, grinding, chewing, dissolution in a solvent, heating, or any combination thereof, and administered orally, wherein   the aversive agent comprises an irritant, and   the particles are from about 0.1 mm to about 2.5 mm in diameter.   
     
     
         30 . The dosage form of  claim 29 , wherein the irritant is selected from the group consisting of capsaicin, a capsaicin analog and mixtures thereof. 
     
     
         31 . The dosage form of  claim 30 , wherein the irritant is a capsaicin analog selected from the group consisting of resiniferatoxin, tinyatoxin, heptanoylisobutylamide, heptanoyl guaiacylamide, other isobutylamides or guaiacylamides, dihydrocapsaicin, homovanillyl octylester, nonanoyl vanillylamide, and mixtures thereof. 
     
     
         32 . The dosage form of  claim 29 , wherein the aversive agent and the material are in the amounts that hinder the pleasure of obtaining a rapid high from the CNS stimulant when the dosage form is tampered with by crushing, shearing, grinding, chewing, dissolution in a solvent, heating, or any combination thereof, and administered orally. 
     
     
         33 . The dosage form of  claim 29 , wherein the irritant is in a sequestered form. 
     
     
         34 . The dosage form of  claim 29 , wherein the irritant is dispersed in the material. 
     
     
         35 . The dosage form of  claim 34 , wherein the material substantially prevents the release of the irritant from the dosage form that is administered orally intact. 
     
     
         36 . The dosage form of  claim 29 , wherein the CNS stimulant comprises methylphenidate or a pharmaceutically acceptable salt thereof. 
     
     
         37 . The dosage form of  claim 29 , wherein the CNS stimulant is the only drug in the dosage form. 
     
     
         38 . The dosage form of  claim 29 , which is free from capsaicin and capsaicin analogs. 
     
     
         39 . An abuse-deterrent oral controlled release dosage form comprising particles comprising a controlled release matrix comprising:
 a CNS stimulant,   an aversive agent, and   a material selected from the group consisting of gums, cellulose ethers, acrylic resins, waxes, shellac, oils and mixtures of any of the foregoing,   the aversive agent and the material are in the amounts that spoil or hinder the pleasure of obtaining a high from the CNS stimulant when the dosage form is tampered with by crushing, shearing, grinding, chewing, dissolution in a solvent, heating, or any combination thereof, and administered orally, wherein   aversive agent comprises an irritant, and   the particles are about 0.1 mm to about 2.5 mm in diameter.   
     
     
         40 . The dosage form of  claim 39 , wherein the CNS stimulant comprises methylphenidate or a pharmaceutically acceptable salt thereof. 
     
     
         41 . The dosage form of  claim 39 , wherein the aversive agent and the material are in the amounts that hinder the pleasure of obtaining a rapid high from the CNS stimulant when the dosage form is tampered with by crushing, shearing, grinding, chewing, dissolution in a solvent, heating, or any combination thereof, and administered orally. 
     
     
         42 . The dosage form of  claim 40 , wherein methylphenidate is the only drug in the dosage form. 
     
     
         43 . The dosage form of  claim 42 , which is free from capsaicin and capsaicin analogs. 
     
     
         44 . The dosage form of  claim 39 , wherein the irritant is a compound capable of imparting an irritating or burning sensation to an abuser. 
     
     
         45 . The dosage form of  claim 39 , wherein the irritant imparts a burning sensation to an abuser when the dosage form is tampered with by crushing, shearing, grinding, chewing, dissolution in a solvent, heating, or any combination thereof, and administered to the abuser orally. 
     
     
         46 . The dosage form of  claim 39 , wherein the aversive agent helps to prevent injection, inhalation and/or oral abuse of the dosage form. 
     
     
         47 . The dosage form of  claim 29 , wherein the irritant is a compound capable of imparting an irritating or burning sensation to an abuser. 
     
     
         48 . The dosage form of  claim 29 , wherein the irritant imparts a burning sensation to an abuser when the dosage form is tampered with by crushing, shearing, grinding, chewing, dissolution in a solvent, heating, or any combination thereof, and administered to the abuser orally.

Join the waitlist — get patent alerts

Track US2019046522A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.